Ieq Capital LLC Acquires 276,649 Shares of Pfizer Inc. $PFE

Ieq Capital LLC boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 59.3% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 742,927 shares of the biopharmaceutical company's stock after purchasing an additional 276,649 shares during the quarter. Ieq Capital LLC's holdings in Pfizer were worth $17,890,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in PFE. Vanguard Group Inc. boosted its position in shares of Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company's stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares in the last quarter. BlackRock Inc. increased its position in Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock valued at $12,754,464,000 after buying an additional 31,412,883 shares in the last quarter. State Street Corp increased its position in Pfizer by 0.5% during the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company's stock valued at $7,481,085,000 after buying an additional 1,357,756 shares in the last quarter. Geode Capital Management LLC raised its stake in Pfizer by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company's stock valued at $3,235,642,000 after buying an additional 1,184,728 shares during the last quarter. Finally, Morgan Stanley boosted its holdings in Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company's stock worth $2,218,929,000 after acquiring an additional 14,342,946 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Stock Down 0.2%

PFE opened at $28.00 on Monday. The stock has a market capitalization of $159.59 billion, a price-to-earnings ratio of 36.84 and a beta of 0.34. The firm has a 50 day moving average price of $25.30 and a 200-day moving average price of $26.25. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $28.75. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter last year, the company posted $0.78 earnings per share. The firm's quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer's dividend payout ratio (DPR) is 226.32%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on PFE. BMO Capital Markets cut their target price on Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, July 13th. JPMorgan Chase & Co. lowered their price target on Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research report on Wednesday, July 8th. Guggenheim dropped their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. Royal Bank Of Canada raised shares of Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective on the stock in a research report on Tuesday, June 9th. Finally, UBS Group restated a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $28.28.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source